Yes, Cosentyx (secukinumab) is a biologic medication. Specifically, it is a fully human monoclonal antibody, meaning it was engineered to mimic proteins naturally produced by the immune system. Unlike traditional medications made through chemical synthesis, biologics like Cosentyx are manufactured using living cells, which makes them larger and more complex molecules.
Understanding what makes Cosentyx a biologic helps explain how it works, why it’s given by injection, and what to expect if you’re prescribed it.
What Makes Cosentyx a Biologic
The term “biologic” refers to drugs derived from biological sources rather than assembled from chemical compounds in a lab. Traditional disease-modifying drugs are small molecules, usually taken as pills, that broadly suppress large portions of your immune system. Biologics are protein-based therapies that zero in on a specific part of the immune response.
Cosentyx falls into a subcategory called interleukin-17A (IL-17A) inhibitors. IL-17A is a signaling protein your immune system uses to trigger inflammation. In conditions like psoriasis, your body overproduces IL-17A, which tells skin cells to multiply too quickly and drives the red, scaly plaques characteristic of the disease. Cosentyx binds directly to IL-17A and blocks it from reaching its receptor on cells, effectively shutting down that one inflammatory signal without broadly suppressing the rest of the immune system.
At the concentrations used in treatment, Cosentyx fully neutralizes IL-17A activity. It does not block the closely related IL-17F protein, and it leaves other immune pathways intact. This selectivity is a hallmark of biologic therapies and a key reason they tend to cause different (and often fewer) side effects than older, broad-acting immunosuppressants.
Conditions Cosentyx Treats
The FDA has approved Cosentyx for six conditions, all of which involve overactive inflammatory signaling:
- Moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis in patients 2 years and older
- Active ankylosing spondylitis in adults
- Non-radiographic axial spondyloarthritis in adults with objective signs of inflammation
- Enthesitis-related arthritis in children 4 years and older
- Moderate to severe hidradenitis suppurativa in adults
Most of these conditions share an underlying pattern: the immune system attacks the body’s own tissues, whether that’s the skin, joints, or connective tissue where tendons meet bone. Cosentyx interrupts that process at the IL-17A level, which is why a single drug can be effective across what seem like very different diseases.
How It’s Given
Because biologics are large protein molecules, your digestive system would break them down before they could work. That’s why Cosentyx is given by injection rather than as a pill. Most people self-inject it under the skin (subcutaneously) in the thigh, abdomen, or upper arm, rotating the injection site each time. An intravenous option also exists for some indications.
The typical schedule for adult plaque psoriasis starts with a loading phase: one injection per week for the first five weeks (weeks 0 through 4). After that, you move to one injection every four weeks. For conditions like psoriatic arthritis and ankylosing spondylitis, the loading phase may be optional, and the dose may start lower, with the option to increase if the response isn’t adequate. Pediatric dosing is weight-based.
How Biologics Differ From Traditional Treatments
If you’ve been on a traditional disease-modifying drug like methotrexate, the shift to a biologic represents a fundamentally different approach. Traditional drugs broadly dampen the immune system. They’re chemically synthesized, taken orally, and tend to affect many immune pathways at once. Biologics are proteins that target a specific set of immune cells or signals, leaving the rest of your defenses more intact.
This precision comes with tradeoffs. Biologics require injections or infusions, cost significantly more than traditional oral medications, and need refrigerated storage. But for many people whose conditions haven’t responded well to conventional therapies, the targeted action of a biologic like Cosentyx offers better disease control with a more predictable side effect profile.
Infection Risk and Side Effects
Because Cosentyx dials down part of your immune response, infections are the primary safety concern. A large Nordic study tracking real-world outcomes found that the first-year risk of a hospitalized infection during Cosentyx treatment was about 3.5%. However, the study noted that this number was largely explained by the fact that Cosentyx tends to be prescribed to patients with more severe, harder-to-treat disease who already carry higher baseline risk.
When researchers compared specific infection types between Cosentyx and older biologic classes (TNF inhibitors), the rates of pneumonia, urinary tract infections, and fungal infections were similarly low across all groups. Notably, no cases of tuberculosis were found during Cosentyx treatment in that study, which is a concern more commonly associated with TNF-blocking biologics.
Common, less serious side effects include upper respiratory infections, diarrhea, and reactions at the injection site. Because IL-17A plays a role in the body’s defense against fungal organisms, your doctor may monitor for fungal infections, particularly candida (yeast) infections, which occur at slightly higher rates compared to some other biologics.
Why the “Biologic” Label Matters
Knowing that Cosentyx is a biologic has practical implications beyond the science. Biologics are typically placed on specialty tiers by insurance plans, which means higher copays and sometimes prior authorization requirements showing that you’ve tried less expensive therapies first. Many biologic manufacturers, including Novartis (which makes Cosentyx), offer patient assistance or copay support programs to offset costs.
The biologic classification also affects what happens when patents expire. Unlike traditional drugs that get generic equivalents, biologics get “biosimilars,” which are highly similar but not identical copies. Biosimilars go through a different, more rigorous approval pathway than standard generics because of the complexity of manufacturing protein-based drugs from living cells.